Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

AIM: To determine the efficacy of rifaximin for hepatic encephalopathy (HE) with the linkage of gut microbiome in decompensated cirrhotic patients. METHODS: Twenty patients (12 men and 8 women; median age, 66.8 years; range, 46-81 years) with decompensated cirrhosis (Child-pugh score > 7) underwe...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaji, Kosuke, Takaya, Hiroaki, Saikawa, Soichiro, Furukawa, Masanori, Sato, Shinya, Kawaratani, Hideto, Kitade, Mitsuteru, Moriya, Kei, Namisaki, Tadashi, Akahane, Takemi, Mitoro, Akira, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Case Control Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743506/
https://www.ncbi.nlm.nih.gov/pubmed/29307995
http://dx.doi.org/10.3748/wjg.v23.i47.8355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743506/
https://www.ncbi.nlm.nih.gov/pubmed/29307995
http://dx.doi.org/10.3748/wjg.v23.i47.8355

Ejemplares similares